• PDF: Delivered by email usually within 48 UK business hours.

Nexavar (Renal Cell Carcinoma) – Analysis and Forecasts to 2022

  • Publication Date:March 2012
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:48

Nexavar (Renal Cell Carcinoma) – Analysis and Forecasts to 2022

Summary

GlobalData's pharmaceuticals report, 'Nexavar (Renal Cell Carcinoma) - Analysis and Forecasts to 2022' provides Nexavar sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Nexavar including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Nexavar including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2012-2022 for Nexavar in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2012-2022 for all seven major markets
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 RCC
      • 2.1.1 Types of Renal Cell Carcinoma
    • 2.2 RCC Market
    • 2.3 Epidemiology
    • 2.4 Pathophysiology
    • 2.5 Etiology
      • 2.5.1 Cigarette Smoking
      • 2.5.2 Obesity
      • 2.5.3 Acquired Cystic Disease
      • 2.5.4 Hypertension
      • 2.5.5 Family History of Kidney Cancer
      • 2.5.6 High Blood Pressure
      • 2.5.7 Usage of Certain Medicines
      • 2.5.8 Advanced Kidney Disease
      • 2.5.9 Gender and Race
      • 2.5.10 Genetic and Hereditary Risk Factors
      • 2.5.11 Symptoms
      • 2.5.12 Diagnosis
    • 2.6 GlobalData Pipeline Report Guidance
  • 3 RCC Disease: Market Characterization
    • 3.1 RCC Disease Market
    • 3.2 RCC Disease Market Forecasts and CAGR
    • 3.3 Drivers for the RCC Disease Market
      • 3.3.1 High Incidence
      • 3.3.2 High Prevalence
      • 3.3.3 Emergence of Targeted Therapies
      • 3.3.4 Large Unmet Need
    • 3.4 Tumor-Node-Metastases (TNM) Classification of RCC
      • 3.4.1 Staging
      • 3.4.2 Grading
      • 3.4.3 Prognosis
    • 3.5 Treatment Options in RCC
      • 3.5.1 Surgery
      • 3.5.2 Radiation therapy
      • 3.5.3 Chemotherapy
      • 3.5.4 Targeted Therapies
      • 3.5.5 Tyrosine Kinase Inhibitors
      • 3.5.6 Mammalian Target of Rapamycin (mTOR) Inhibitor
      • 3.5.7 Vascular Endothelial Growth Factor (VEGF) Inhibitor
      • 3.5.8 Treatment by Stage
    • 3.6 Classification of Patients with RCC
  • 4 Nexavar (sorafenib)
    • 4.1 Introduction
    • 4.2 Mechanism of Action
    • 4.3 Clinical Studies
    • 4.4 Approval History of Nexavar
    • 4.5 Factors Affecting Sales of Nexavar
      • 4.5.1 First Mover Advantage
      • 4.5.2 Rejection in the UK
      • 4.5.3 Increasing Competition
    • 4.6 Drug Evaluation
      • 4.6.1 Drug Risk Benefit Score
      • 4.6.2 Intensity of Competition
    • 4.7 Sales Forecasts
      • 4.7.1 Target Patient Pool of Nexavar
      • 4.7.2 Dosing
      • 4.7.3 Market Penetration
      • 4.7.4 Annual Cost of Therapy
      • 4.7.5 Sales Projections of Nexavar
  • 5 RCC Market: Appendix
    • 5.1 Market Definitions
    • 5.2 Abberiviations
    • 5.3 Research Methodology
      • 5.3.1 Coverage
      • 5.3.2 Secondary Research
      • 5.3.3 Forecasting
      • 5.3.4 Number of Patients Approved to Take the Drug
      • 5.3.5 Net Penetration of Drug
      • 5.3.6 Net Annual Dosing
      • 5.3.7 Annual Cost of Therapy
    • 5.4 Drug Sales Estimates Model
    • 5.5 Contact Us
    • 5.6 Disclaimer
    • 5.7 Sources
    • 1.1 List of Tables
    • Table 1: RCC, Incidences and Mortality, 2008-2030
    • Table 2: RCC, TNM Classification
    • Table 3: RCC, Treatment Guidelines
    • Table 4: Nexavar, Renal Cell Carcinoma, Phase III Clinical Study Results
    • Table 5: Approval History of Nexavar
    • Table 6: Renal Cell Carcinoma, Nexavar, Drug Risk Benefit Score
    • Table 7: Nexavar, Renal Cell Carcinoma, Global, Annual Cost of Therapy ($), 2011
    • Table 8: Nexavar, Renal Cell Carcinoma, Global, Sales Estimates ($m), 2006-2022
    • Table 9: Nexavar , Renal Cell Carcinoma, The US, Sales Estimates ($m), 2006-2022
    • Table 10: Nexavar, Renal Cell Carcinoma, The UK, Sales Estimates ($m), 2006-2022
    • Table 11: Nexavar, Renal Cell Carcinoma, France, Sales Estimates ($m), 2006-2022
    • Table 12: Nexavar, Renal Cell Carcinoma, Germany, Sales Estimates ($m), 2006-2022
    • Table 13: Nexavar, Renal Cell Carcinoma, Italy, Sales Estimates ($m), 2006-2022
    • Table 14: Nexavar, Renal Cell Carcinoma, Spain, Sales Estimates ($m), 2006-2022
    • Table 15: Nexavar, Renal Cell Carcinoma, Japan, Sales Estimates ($m), 2008-2022
    • 1.2 List of Figures
    • Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2010
    • Figure 2: Total number of cigarettes consumed, The US, 1976-2006
    • Figure 3: RCC, Global, Market Size Forecasts ($bn), 2010-2022
    • Figure 4: RCC, Global, Incidence (in million), 2008-2030
    • Figure 5: Oncology, Worldwide, Incidence (in million), 2008-2030
    • Figure 6: RCC, TNM Staging System
    • Figure 7: RCC, Marketed drug targets
    • Figure 8: RCC, Surgical Management
    • Figure 9: Treatment Algorithm for Metastatic Renal Cell Carcinoma
    • Figure 10: Classification of Patients with RCC
    • Figure 11: Renal Cell Carcinoma, Nexavar, Drug Model Diagram
    • Figure 12: Nexavar, Renal Cell Carcinoma, Global, Sales Estimates ($m), 2006-2022
    • Figure 13: Nexavar , Renal Cell Carcinoma, The US, Sales Estimates ($m), 2006-2022
    • Figure 14: Nexavar, Renal Cell Carcinoma, The UK, Sales Estimates ($m), 2006-2022
    • Figure 15: Nexavar, Renal Cell Carcinoma, France, Sales Estimates ($m), 2006-2022
    • Figure 16: Nexavar, Renal Cell Carcinoma, Germany, Sales Estimates ($m), 2006-2022
    • Figure 17: Nexavar, Renal Cell Carcinoma, Italy, Sales Estimates ($m), 2006-2022
    • Figure 18: Nexavar, Renal Cell Carcinoma, Spain, Sales Estimates ($m), 2006-2022
    • Figure 19: Nexavar, Renal Cell Carcinoma, Japan, Sales Estimates ($m), 2008-2022
    • Figure 20: Nexavar, Renal Cell Carcinoma, Global, Sales Distribution by Country (%), 2019
    • Figure 21: Patients Approved for the Drug
+44 20 8816 8548

Ask a question about Nexavar (Renal Cell Carcinoma) – Analysis and Forecasts to 2022

Enter the characters you see in the picture below
Captcha